The Role of Cortisol/ACTH Ratio for Screening of Subclinical Hypercortisolism in Patients with Adrenal Incidentalomas

Abstract

Introduction The cortisol/ACTH ratio was supposed to be helpful in the screening of subclinical hypercortisolism (SHC) in the published literatures. This study assessed the cortisol/ACTH ratio in patients with adrenal incidentaloma (AI) confirmed to have SHC and investigated its role for screening SCS in patients with AI.

Methods This descriptive retrospective study included 183 patients with AIs [45 with SHC and 138 with non-functional adenoma (NFA)]. Cortisol and ACTH levels were measured at 8:00, 16:00, and 0:00, and the cortisol/ACTH ratio was calculated. ROC curve was used to evaluate efficacy of the cortisol/ACTH ratio, explore the best cut-off value and its corresponding sensitivity and specificity.

Results The cortisol/ACTH ratios at all time points were significantly higher in the SHC group than the NFA group (P<0.05) and were significantly correlated with serum cortisol levels after the 1-mg dexamethasone suppression test (DST). Area Under the Curve (AUC) of the cortisol/ACTH ratio at 0:00 and midnight serum cortisol levels were 0.893 (0.843–0.943) and 0.831 (0.765–0.806), respectively. A cortisol/ACTH ratio at 0:00 cut-off of 32.18 nM/pM showed a sensitivity of 100% and specificity of 39.1%. The optimal cut-off was 68.83 nM/pM (sensitivity 86.7%, specificity 75.4%).

Conclusions Patients with SHC have a higher cortisol/ACTH ratio than those with NFAs. The cortisol/ACTH ratio is significantly correlated with serum cortisol after the 1-mg DST. The diagnostic performance of the cortisol/ACTH ratio at 0:00 is superior to midnight serum cortisol. Therefore, the cortisol/ACTH ratio at 0:00 may be a reliable parameter for SHC screening in patient with AI.

^* Lele Li and Guoqing Yang contributed equally to this article.

• References

• 1 Chidiac RM, Aron DC. Incidentaloma. A disease of modern technology. Endocrinol Metab Clin North Am 1997; 26: 233-253
• 2 Barzon L, Sonino N, Fallo F. et al. Prevalence and natural history of adrenal incidentaloma. Eur J Endocrinol 2003; 149: 273-285
• 3 Singh PK, Buch HN. Adrenal incidentaloma: evaluation and management. J Clin Pathol 2008; 61: 1168-1173
• 4 Young Jr WF. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 2007; 356: 601-610
• 5 Cawood TJ, Hunt PJ, O’Shea D. et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur J Endocrinol 2009; 161: 513-527
• 6 Mantero F, Terzolo M, Arnaldi G. et al. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the italian society of endocrinology. J Clin Endocrinol Metab 2000; 85: 637-644
• 7 Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J Clin Endocrinol Metab 2011; 96: 1223-1236
• 8 Terzolo M, Pia A, Reimondo G. Subclinical Cushing’s syndrome: definition and management. Clin Endocrinol 2012; 76: 12-18
• 9 Nieman LK, Biller BM, Findling JW. et al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1526-1540
• 10 Zeiger MA, Thompson GB, Duh QY. et al. American association of clinical endocrinologists and american association of endocrine surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract 2009; 15 (Suppl. 01) 1-20
• 11 Shiwa T, Oki K, Yamane K. et al. Significantly high level of late-night free cortisol to creatinine ratio in urine specimen in patients with subclinical Cushing’s syndrome. Clin Endocrinol 2013; 79: 617-622
• 12 Olsen H, Olofsson L, Mjoman M. Cortisol secretion from adrenal adenomas discovered as incidentalomas is responsive to ACTH. Clin Endocrinol 2014; 80: 335-341
• 13 Terzolo M, Stigliano A, Chiodini I. et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol 2011; 164: 851-870
• 14 Libe R, Dall’Asta C, Barbetta L. et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol 2002; 147: 489-494
• 15 Joubert M, Louiset E, Rego JL. et al. Aberrant adrenal sensitivity to vasopressin in adrenal tumors associated with subclinical or overt autonomous hypercortisolism: is this explained by an overexpression of vasopressin receptors?. Clin Endocrinol 2008; 68: 692-699
• 16 Reznik Y, Lefebvre H, Rohmer V. et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin Endocrinol 2004; 61: 311-319
• 17 Beuschlein F, Fassnacht M. Klink et al. ACTH-receptor expression, regulation and role in adrenocortical tumor formation. Eur J Endocrinol 2001; 144: 199-206
• 18 Sereg M, Toke J, Patocs A. et al. Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing’s syndrome. Steroids 2011; 76: 38-42
• 19 Gagliardi L, Torpy DJ. Subclinical Cushing’s syndrome in adrenal incidentaloma: a common problem or an artefact of current diagnostic testing?. Clin Endocrinol 2010; 72: 277-278
• 20 Bencsik Z, Szabolcs I, Kovacs Z. et al. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a good predictor of hormonal activity in nonselected patients with incidentally detected adrenal tumors. J Clin Endocrinol Metab 1996; 81: 1726-1729
• 21 Born J, Ditschuneit I, Schreiber M. et al. Effects of age and gender on pituitary-adrenocortical responsiveness in humans. Eur J Endocrinol 1995; 132: 705-711